<DOC>
	<DOCNO>NCT02068222</DOCNO>
	<brief_summary>The purpose study evaluate safety antiviral effect ABT-450/r ABT-530 coadministered without Ribavirin adult genotype 3 HCV infection .</brief_summary>
	<brief_title>A Study Evaluate Safety Antiviral Effect ABT-450/Ritonavir ABT-530 Coadministered With Without Ribavirin Adults With Genotype 3 Hepatitis C ( HCV ) Infection</brief_title>
	<detailed_description>Once efficacy safety data obtain participant administer ABT-450/r + ABT-530 + RBV weight-based ( Arm 1 ) Study M14-213 , decision make end study subject enrol Arm 2 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female ( nonchild bear potential ) 18 70 year age Body Mass Index â‰¥18 &lt; 38 kg/m2 . Chronic HCV genotype 3 infection prior study enrollment never receive antiviral treatment HCV . Subject plasma HCV RNA level &gt; 10,000 IU/mL Screening . Sexually active male must sterile , male partner , agree use two effective form birth control 7 month stop study drug . History severe , lifethreatening significant sensitivity drug . Positive test result Hepatitis B surface antigen ( HBsAg ) antiHuman Immunodeficiency virus antibody ( HIV Ab ) . Prior therapy treatment HCV . Any current past clinical evidence cirrhosis . Any cause liver disease chronic HCVinfection . HCV genotype coinfection HCV genotype . Use contraindicate medication within 2 week 10 halflives dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Interferon Free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Hepatitis C Genotype 3</keyword>
</DOC>